drugset / Trial / NCT00017173

S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat

NCT00017173

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy with the p53 gene may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy plus surgery followed by cisplatin and radiation therapy in treating patients who have newly diagnosed resectable stage III or stage IV cancer of the mouth or throat.

Timeline

Start
2003-02
Primary completion
2007-05
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CONTUSUGENE LADENOVEC Unknown Other
Background Cisplatin Other / unclassified 100 mg/m2 Intravenous

Indications